IHS Chemical Week

Regions :: North America :: U.S.

Lonza to Supply Stem Cell Therapy Drug to Maryland Biotech Firm

4:25 PM MDT | July 14, 2008 | Alex Scott

Lonza says it has secured a deal with biotech firm Osiris Therapeutics (Columbia, MD) to manufacture what it says could be the world’s first stem cell drug. The agreement calls for Lonza to manufacture Osiris’s Prochymal stem cell therapy, which is being evaluated in phase III clinical trials for three medical applications including Crohn’s disease. Lonza says it will invest “millions of dollars” to build a Prochymal facility at its Walkersville, MD site. Financial terms were not disclosed. von Hippel: A focus on profitable products...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa